Mutations in PIK3CA, which encodes the p110α subunit of the insulin-activated phosphatidylinositol-3 kinase (PI3K), and loss of function mutations in PTEN, which encodes a phosphatase that degrades the phosphoinositide lipids generated by PI3K, are among the most frequent events in human cancers 1,2 . However, pharmacological inhibition of PI3K has resulted in variable clinical responses, raising the possibility of an inherent mechanism of resistance to treatment. As p110α mediates virtually all cellular responses to insulin, targeted inhibition of this enzyme disrupts glucose metabolism in multiple tissues. For example, blocking insulin signalling promotes glycogen breakdown in the liver and prevents glucose uptake in the skeletal muscle and adipose tissue, resulting in transient hyperglycaemia within a few hours of PI3K inhibition. The effect is usually transient because compensatory insulin release from the pancreas (insulin feedback) restores normal glucose homeostasis 3 . However, the hyperglycaemia may be exacerbated or prolonged in patients with any degree of insulin resistance and, in these cases, necessitates discontinuation of therapy 3-6 . We hypothesized that insulin feedback induced by PI3K inhibitors may reactivate the PI3K-mTOR signalling axis in tumours, thereby compromising treatment effectiveness 7,8 . Here we show, in several model tumours in mice, that systemic glucoseinsulin feedback caused by targeted inhibition of this pathway is sufficient to activate PI3K signalling, even in the presence of PI3K inhibitors. This insulin feedback can be prevented using dietary or pharmaceutical approaches, which greatly enhance the efficacy/ toxicity ratios of PI3K inhibitors. These findings have direct clinical implications for the multiple p110α inhibitors that are in clinical trials and provide a way to increase treatment efficacy for patients with many types of tumour.
monitored their blood glucose levels over time after treatment (Fig. 1a , Extended Data Fig. 1a, b ). As expected, many of these agents caused substantial increases in blood glucose levels. Notably, the hyperglycaemia resolved after only a few hours without additional intervention, suggesting that PI3K signalling had been reactivated in muscle and liver despite the presence of the drug. For each of the agents that caused an increase in blood glucose, there was also an increase in the amount of insulin released into the serum as measured by enzyme-linked immunosorbent assays (ELISAs) for insulin over time ( Fig. 1b ) and c-peptide, which is clinically used as a surrogate for insulin over time [12] [13] [14] (Fig. 1c , Extended Data Fig. 1c, d ). To assess whether these PI3K inhibitorinduced spikes in glucose and insulin affected tumours, we performed fluorodeoxyglucose positron emission tomography (FDG-PET) on mice bearing orthotopic Kras-Tp53-Pdx-Cre (KPC) tumour allografts in the pancreas 15 . We observed an increase in glucose uptake in these tumours 90 min after PI3K inhibition as compared to vehicle-treated mice, indicating that the spikes in insulin could be causing transient increases in glucose uptake in these tumours (Fig. 1d) .
To test whether these spikes in insulin were stimulating PI3K signalling in the context of PI3K inhibition, we treated KPC cells in vitro with PI3K inhibitors in the presence or absence of 10 ng ml −1 insulin (the amount observed in the mice within 15-30 min of drug administration; Fig. 1d ). This level of insulin was sufficient to partially rescue PI3K signalling in the continued presence of PI3K inhibitors, as indicated by partial re-activation of phosphorylated AKT (pAKT) and almost complete reactivation of phosphorylated S6 (pS6), a reporter of growth signalling through the mTORC1 complex ( Fig. 2a, Supplementary Fig. 1 ). In addition, this enhanced signalling correlated with a partial recovery of cellular proliferation (Fig. 2b, c) . Insulin also stimulated proliferation in the presence of a PI3K inhibitor in a variety of other tumour cell lines and patient-derived organoids 16 (Extended Data Fig. 2a-g) . The amount of stimulation was not uniform across all cell lines, as would be expected in tumours with variable expression of the insulin receptor and differential dependence on PI3K signalling for growth. These observations support the conclusions that insulin is a potent activator of PI3K signalling in certain tumours, and that elevation of serum insulin following administration of a PI3K inhibitor can reactivate PI3K signalling and potentially other PI3K-independent responses to insulin in both normal tissues and tumours.
Research into diabetes and treatment of patients with diabetes have resulted in the development of numerous approaches to manage blood glucose and insulin levels. Using these tools, we sought to identify ways to augment PI3K inhibitor therapies by circumventing the acute glucose-insulin feedback. We chose to evaluate metformin and inhibitors of sodium-glucose co-transporter 2 (SGLT2), both of which are Letter reSeArCH extensively used to treat diabetes [17] [18] [19] [20] , as well as a ketogenic diet in our mouse models of cancer. Metformin was chosen because it has an extremely low toxicity profile and is commonly used in patients with diabetes or pre-diabetes to increase their insulin sensitivity, which reduces hyperglycaemia and insulin levels 20 . Metformin is also commonly used in trials of PI3K inhibitors to manage patients who become chronically hyperglycaemic [21] [22] [23] . SGLT2 inhibitors are also generally well tolerated and work by inhibiting the glucose transporters that are responsible for the reabsorption of glucose in the kidney. The rationale for using a ketogenic diet was to deplete hepatic glycogen stores and thereby limit the acute release of glucose from the liver that occurs following PI3K inhibition. Ketogenic diets have been used to treat patients with epilepsy since the 1970s and have been shown to reduce blood glucose levels and increase insulin sensitivity as compared to normal western diets 7, 24 .
To test whether these approaches could limit acute glucose-insulin feedback and alter signalling in tumours, treatment-naive mice bearing KPC tumour allografts were placed on a ketogenic diet or treated with metformin for 10 days before a single treatment with the PI3K inhibitor BKM120. During this treatment, blood glucose was monitored and, after 3 h, c-peptide (a surrogate for blood insulin) was measured ( Fig. 3a, b ). In some mice, tumours were removed after 90 min and stained for pS6, a reporter of mTORC1 activity ( Fig. 3c, d) . These results demonstrated that pretreatment with metformin had only a minimal effect on the PI3K inhibitor-induced elevation in blood glucose and insulin levels or on growth signalling through mTORC1. By contrast, both the SGLT2 inhibitor and the ketogenic diet decreased hyperglycaemia and reduced the release of insulin in response to BKM120 treatment, and these effects correlated with reduced signalling through mTORC1 in the tumour. Similar effects were seen in mice treated with the p110α-specific inhibitor BYL-719, in which the response of KPC allografts to BYL-719 was enhanced in a manner concordant with the relative ability of each treatment to reduce serum insulin levels ( Fig. 3e -g, Extended Data Fig. 3a-d) .
Various hormones and metabolites can reactivate growth in the setting of PI3K inhibition. To test whether the enhancement in tumour signalling and growth was mediated directly by insulin, we generated a doxycycline-inducible short hairpin RNA (shRNA) to target the insulin receptor in KPC tumours (Extended Data Fig. 4a , Supplementary  Fig. 2 ). Induction of this hairpin in the absence of a PI3K inhibitor had little effect on tumour growth. However, induction of the hairpin at the initiation of BYL719 treatment resulted in tumour shrinkage and was almost as effective as the ketogenic diet ( Fig. 4a ). This result supports a model in which the insulin receptor does not have a major role in tumour growth until supra-physiological amounts of insulin are released following treatment with a PI3K inhibitor. The specificity of this effect was further corroborated by combining the PI3K inhibitor BKM120 with OSI-906, which inhibits the insulin receptor and the IGF1 receptor. This had a great effect on the growth of KPC allografts than either drug alone (Extended Data Fig. 4b -g). Notably, feeding a ketogenic diet to mice bearing tumours with insulin receptor knockdown ( Fig. 4a ) or to mice treated with OSI-906 (Extended Data Fig. 4b ) in the absence of a PI3K inhibitor provided little or no enhancement of therapeutic response.
To further test whether the improved response to PI3K inhibitors while on a ketogenic diet is a consequence of lowering blood insulin levels, we attempted to 'rescue' the PI3K reactivation using exogenous insulin. A cohort of mice bearing Pik3ca mutant breast tumour allografts were treated with a combination of a ketogenic diet and BYL-719, and then given 0.4 mU of insulin 15 min after each dose of PI3K inhibitor (Fig. 4b ). The addition of insulin markedly reduced the therapeutic benefit of supplementing PI3K inhibitor therapy with a ketogenic diet, and also rescued tumour growth in allografted KPC tumours (Extended 
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Data Fig. 4h ). It should be noted that the combination of the ketogenic diet, insulin, and BYL-719 was not well-tolerated in young mice, so ethical endpoints were reached in this cohort. Together these data strongly support a model in which a ketogenic diet improves responses to PI3K inhibitors by reducing blood insulin and the consequent ability of insulin to activate the insulin receptor in tumours.
In this study, we evaluated the ability of a ketogenic diet to improve responses to PI3K inhibitors in tumours with a wide range of genetic aberrations. Therapeutic benefit was observed in patient-derived xenograft models of advanced endometrial adenocarcinoma (harbouring a PTEN deletion and PIK3CA mutation) and bladder cancer (FGFRamplified) as well as in syngeneic allograft models of Pik3ca mutant mice bearing syngeneic K8484 KPC allografted tumours and pretreated with metformin, SGLT2-inhibitor (SGLT2i), or a ketogenic diet, after treatment with a single dose of BKM120 (n = 5 mice). P values calculated by two-way repeated measures ANOVA for metformin, SGLT2i, and the ketogenic diet were 0.2136 (not significant), <0.0001, and 0.007, respectively. b, Mean (± s.d.) blood levels of c-peptide of the same mice (n = 5) taken 180 min after treatment with BKM120. P values calculated by unpaired two-sided t-test for metformin, SGLT2i, and ketogenic diet were 0.7566 (not significant), 0.0386, and 0.0117, respectively. c, Immunohistochemical staining for pS6 (ser-235) to observe the level of active PI3K signalling in these tumours. d, Quantification of staining shown as mean (± s.d.) number of positive cells per high power field (HPF) (n = 5 mice per group). P values comparing pS6-positive cells in tumours treated with BKM120 alone compared to those treated with BKM120 in combination with metformin, SGLT2i, or the ketogenic diet using two-sided t-tests were 0.6186, <0.0001 and <0.0001, respectively. e, IVIS images of luciferase reporter luminescence in mice with KPC K8484 tumours after 12 days of treatment with the PI3Kα-specific inhibitor BYL-719 alone or in combination with metformin, ketogenic diet, or SGLT2i (n = 10 tumours per arm). f, Mean (± s.d.) luminescence from images in of these tumours. g, Survival analysis of these mice. P = 0.0019 and 0.0001, respectively, as determined by log-rank (Mantel-Cox) test.
breast cancer and MLL-AF9 driven acute myeloid leukaemia (AML) ( Fig. 4c , Extended Data Figs. 5-7).
The addition of the ketogenic diet improved drug efficacy with an array of agents that target the PI3K pathway in addition to BKM120 and BYL719, including the pan-PI3K inhibitor GDC-0941, the PI3Kβ-sparing compound GDC-0032, the mTOR/PI3K dual inhibitor GDC-0980, and the recently approved PI3K-α/δ inhibitor Copanlisib (Extended Data Fig. 5 ). It is important to note that treatment with the ketogenic diet alone had variable effects in different tumour models, indicating that the dietary changes themselves were insufficient to cause the tumour responses observed across the mouse models. In some instances, such as the AML model, the ketogenic diet alone accelerated disease progression, suggesting that this diet may be detrimental for some patients with cancer when used in isolation.
Our data suggest that insulin feedback limits the efficacy of PI3K inhibition in several tumour models. By reducing the systemic insulin response, the addition of a ketogenic diet to BKM120 reduced immunohistochemical markers of insulin signalling in PTEN/PIK3CA mutant endometrial patient-derived xenograft (PDX) tumours, compared to tumours from mice treated with BKM120 alone. In these tumours, the ketogenic diet enhanced the ability of BKM120 to reduce levels of phosphorylated insulin receptor, phosphorylated AKT and phosphorylated S6 and this reduction in signalling correlated with decreased levels of proliferation as shown by Ki67 staining, and increased levels of apoptosis as indicated by cleaved caspase 3 staining ( Fig. 4d, e ).
While these data do not exclude insulin-independent effects of combining PI3K inhibition with anti-glycaemic therapy, they demonstrate that using this approach has the potential to substantially increase the therapeutic efficacy of these compounds. In light of these results, it may also be important to think about how common clinical practices such as intravenous glucose administration, glucocorticoid use, or providing patients with glucose-laden nutritional supplements may impact therapeutic responses. As therapeutic agents that target this critical oncogenic pathway are brought through clinical trials, they should be paired with strategies such as SGLT2 inhibition or the ketogenic diet to limit this self-defeating systemic feedback. , and ki67 of the tumours from d taken 4 h after the last treatment with vehicle, ketogenic diet, BKM120, or the combination of the ketogenic diet with BKM120 (BKM120 + keto). Quantification is depicted as score per HPF, four images were taken for each of the n = 5 mice. P values from two-sided t-tests comparing the blinded scoring in BKM120-treated tumours with those treated with BKM120 + ketogenic diet were 0.005, 0.005, 0.017 and 0.028 for pINSR, pAKT, pS6 and Cl. Casp 3, respectively. H-score denotes intensity and percent of cells with staining at the cell membrane.
Online content

Letter reSeArCH
MEthodS
Mice procurement and treatment. All animal studies were conducted following IACUC approved animal protocols (#2013-0116) at Weill Cornell Medicine and (AC-AAAQ5405) at Columbia University. Ethical requirements for the treatment of animals were followed for all of the animal studies as per institutional guidelines. Mice were maintained in temperature-and humidity-controlled specific pathogen-free conditions on a 12-h light/dark cycle and received a normal chow diet (PicoLab Rodent 20 5053 laboratory Diet St. Louis, MO) or ketogenic diet (Thermo-Fisher AIN-76A) with free access to drinking water. Diets were composed as indicated in Supplementary Table 1 . Owing to the nature of the diets used, blinding was not possible. No statistical methods were used to predetermine sample size.
For solid tumour studies Nude (genotype) and C57/BL6 mice were purchased at 8 weeks of age from Jackson laboratories (Bar Harbour, ME). They were injected with 0.5-1 × 10 6 cells in a 1:1 mix of growth media and matrigel (Trevigen, # 3433-005-R1) and tumours were allowed to grow to a minimum diameter of 0.6cm before the initiation of treatment. Tumours that did not meet this criterion at the time of treatment initiation were not used for experimentation.
For AML studies 10-12 weeks old male C57BL/6J mice were used for MLL-AF9 Ds-Red AML study (Approved protocol AC-AAAQ5405). For pre-treatment study with MLL-AF9 Ds-Red cells, keto and Keto/BKM group mice were given a ketogenic diet for 10 days before injection with MLL-AF9 Ds-Red cells (2 × 10 5 per mouse in 200 μl) via lateral tail vein. The day after iv injection, the mice were given 0.5% carboxymethyl cellulose (CMC) as vehicle control or BKM120 (37.5 mg/kg) by oral gavage for two weeks (5 out of 7 days). The mice were euthanized after two-week treatment to check the bone marrow for AML progress. The mice were euthanized and one femur and tibia were removed from each mouse. The bone marrow cells were flushed with PBS (2% FBS). The red blood cells were lysed with ACK lysis buffer (Invitrogen). DAPI was used to exclude dead cells. The DS-red AML cells from the BM were analysed with BD LSRII. The tumour progress was also monitored via IVIS spectrum machine. For co-current treatment study with MLL-AF9 Ds-Red cells, the mice were injected with MLL-AF9 Ds-Red cells (2 × 10 5 per mouse in 200 μl) via lateral tail vein. The day after iv injection, the mice were given vehicle or BKM120 (37.5 mg/kg) by oral gavage for two weeks. The Keto or Keto/BKM group were changed to a ketogenic diet on the same day. The mice were euthanized after two-week treatment to check the bone marrow for AML progress.
To check whether Keto/BKM treatment affects the AML engraftment, Keto and Keto/BKM group mice were given a ketogenic diet for 10 days, then treated with vehicle or BKM120 by oral gavage for two weeks. The mice were then injected with MLL-AF9 Ds-Red cells (2 × 10 5 per mouse in 200 μl) via lateral tail vein. Two weeks after the iv injection, the mice were euthanized to check the bone marrow for AML burden.
The survival study, pre-treatment study, and co-current treatment were conducted at the same time. The mice were treated with vehicle or BKM120 (5 out of 7 days) until spontaneous death, or mice were euthanized when they appeared to be very sick (reduced spontaneous activity, unkempt coat, and dehydrated appearance), achieved body weight loss over 20%, or demonstrated signs of limb paralysis. Compounds. GDC-0032, MK2206, BEZ235, BKM-120, GDC-0941, GDC-0980, and Canagliflozin were all procured from Medchem Express (Monmouth Junction, NJ) and given via oral gavage in 100 μl. Metformin was procured from Sigma Aldrich (St. Louis, MO). BAY-80 6946 and OSI-906 came from Sellechem catalogue #S2802 and #S1091 respectively. The targeting information for these compounds is displayed in Supplementary Table 3 . IC 50 data was obtained from the Selleckchem website (Selleckchem.com). The canagliflozin was administered 60 min before the PI3K pathway inhibitors so that its optimal efficacy lined up with the peak glucose levels. Mice treated with metformin were pretreated for 10 days before BKM120 treatment. Ketogenic diet was initiated at the time of initial PI3K inhibitor treatment unless otherwise stated. Doxycycline was procured from Sigma (St. Louis, Missouri) catalogue number D3072-1ML and administered via intraperitoneal injection once daily at a dose of 3mg/kg. Culture. Murine pancreas cell lines were a gift from K. Olive, Columbia University 15 . Murine breast lines were a gift from R. Parsons, Mount Sinai School of Medicine. PDX models were derived by the Englander Institute of Precision Medicine in accordance with an IRB approved protocol as described 16, 25 . Cell lines HEK293, HCC-38, MDA-MB-468, PC-3, BT-549 were purchased from ATCC and grown in DMEM supplemented with 10% FBS and 1% Pen/Strep. HCT-116 and DLD-1 isogenic lines with and without PTEN deletion were kindly provided by the Laboratory of Todd Waldman 26 . A chart of cells/organoids is in Supplementary  Table 2 , with known oncogenic alterations as described in publications cited above or as available from the ATCC (https://www.atcc.org/~/media/PDFs/Culture%20 Guides/Cell_Lines_by_Gene_Mutation.ashx). Authentication was not required for the cells that came directly from ATCC. Key genetic alterations of mouse lines were confirmed via genotyping for transgenes. Mutant HCT-116 and DLD-1 lines from the Waldman lab were validated by western blot analysis to demonstrate PTEN deletion.
For signalling assays, cells were washed 1x in PBS and placed in starvation media (-FBS) for 6-18 h depending upon cell line, and treated 1 h before harvesting with PI3K inhibitors as indicated alone or in combination with insulin 10 min before harvesting. Three dimensional culture and dose response experiments of patient derived organoids were run as previously described 16 . In brief, ~1,000 cells were plated in 10 μl of 1:1 matrigel to culture media in 96 well angiogenesis plates and allowed to solidify for 30 min at 37 degrees before 70ul of culture media was added. Organoids were then treated in triplicate in a log scale dose response and CellTiter-Glo assay (Promega) was run at 96 h to determine the IC 50 values.
Knockdown of insulin receptor was achieved using a doxycyclineinducible shRNA strategy. For generation of miR-E shRNAs, 97-mer oligonucleotides were purchased (IDT Ultramers) coding for predicted shR-NAs using an siRNA predictional tool Splash RNA, http://splashrna.mskcc. org/ 27 . Oligonucleotides were PCR amplified using the primers miRE-Xho-fw (5′-TGAACTCGAGAAGGTATATTGCTGTTGACAGTGAGCG-3′) and miRE-Eco-rev (5′-TGAACTCGAGAAGGTATATTGCTGTTGACAGTGAGCG-3′). PCR products were purified and both PCR product and LT3GEPIR 28 vectors were double digested with EcoRI-HF and XhoHI. PCR product and vector backbone were ligated and transformed in Stbl3 competent cells and grown at 32 °C overnight. Colonies were screened using the primer miRE-fwd (5′-TGTTTGAATGAGGCTTCAGTAC-3′). R en il la, T GC TG TT GA CA GT GA GC-GC AG GA AT TA TA AT GC TT AT CTATAGTGAAGCCACAGAT GTATAGATAAGCATTATAATTCCTATGCCTACTGCCTCGGA; INSR4, T GC TGTTGACAGTGAGCGCGGGGTTCATGCTGTTCTACAATAGTGAAG CCACAGATGTATTGTAGAACAGCATGAACCCCATGCCTACTGCCTCGGA. Immunoblotting. Cell lysates were prepared in 1x CST Cell Lysis Buffer #9803, (Danvers MA). Total protein concentration was evaluated with the BCA kit (Pierce) 23227). The lysates were run out on 4-20% Tris-Glycine Gels (ThermoFisher, Carlsbad CA). Primary antibodies against pAKT473, pAKT308, pS6, pTYR, AKT, and S6 were procured from Cell Signaling (Danvers, MA), and were used overnight at 1:1,000 in 5% bovine serum albumin. Actin and tubulin antibodies came from Sigma Aldrich and were used at 1:5,000 in 5% milk. All these antibodies were visualized with HRP conjugated secondary antibodies from Jackson Immuno at 1:5,000 in 5% milk. Immunohistochemistry. Tumour sections (3 μm) were antigen retrieved with 10 mmol/L citrate acid, 0.05% Tween 20, pH6.0, and incubated with antibodies as indicated (Ki67 (Abcam, ab16667) 1:500; cleaved caspase-3 (Asp175; 5A1E; Cell Signaling Technology, 9664) 1:200; phospho-INSR (Tyr 1162; Thermo Fisher #AHR0271) 1:100; phospho-AKT (Ser473; Cell Signaling Technology, 8101) 1:20; and phospho-S6 ribosomal protein (Ser235/236; Cell Signaling Technology, 2211) 1:300). Blood measurements. For assessment of blood glucose, 10 μl of blood was taken from the tail of mice before treatment (time 0) and then again at the indicated time points (15, 30, 60, 90 , 120,180 min) using a OneTouch Ultra Glucometer. At end point >100 μl of blood was drawn from the mice into EDTA tubes (Sarstedt #16.444). Blood was centrifuged (10,000g for 10 min at 4 °C), and plasma was stored at −20 °C. Plasma β-hydroxybutyrate, triglyceride (Stanbio Laboratory, Boerne, TX), serum insulin, and c-peptide (APLCO Diagnostics, Salem, NH) levels were quantified by ELISA. FDG-PET. Male c57/bl6 mice (n = 4/arm) bearing orthotopic pancreatic adenocarcinoma allografts were injected with 200-250 μCi [ 89 Zr]liposomes (3-4 μmol lipid) in 200-250 μL PBS solution into the tail vein. At the time of peak blood insulin feedback 90 min post BKM120 injection animals were anaesthetized and scans were then performed using an Inveon PET/CT scanner (Siemens Healthcare Global). Whole body PET scans were performed recording a minimum of 50 million coincident events, with a duration of 10 min. The energy and coincidence timing windows were 350−750 keV and 6 ns. The data were normalized to correct for non-uniformity of response of the PET, dead-time count losses, positron branching ratio, and physical decay to the time of injection. The counting rates in the reconstructed images were converted to activity concentrations (percentage injected dose [%ID] per gram of tissue) by use of a system calibration factor derived from the imaging of a phantom containing 89 Zr. Images were analysed using ASIPro VMTM software (Concorde Micro-systems). Quantification of activity concentration was done by averaging the maximum values in at least 5 ROIs drawn on adjacent slices of the pancreatic tumours. Reporting summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this paper. 
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Extended Data Fig. 1 | Blood glucose and c-peptide levels after treatment with agents that target the PI3K pathway. a, b, Mean ± s.d. blood glucose levels over time where time 0 is the time of treatment with the indicated inhibitor. n = 5 and 3 mice per arm for a and b, respectively. c, d, Mean ± s.d. c-peptide levels from mice in a and b taken 240 and 180 min after treatment with indicated inhibitors. c, n = 5 for vehicle, BKM120, GDC-0941, and GDC-0980; n = 4 for BEZ235; n = 3 for RAD001. D, n = 3 mice per arm. As a surrogate for total insulin release, c-peptide levels show that the PI3K and IGFR/INSR inhibitors markedly increase insulin release. In all cases, compounds that caused acute increases in blood glucose also increased serum insulin.
Extended Data Fig. 2 | Effect of feedback levels of insulin observed in Fig. 1 on BKM120 efficacy in vitro. a, Proliferation in minimal growth medium of cells whose growth is partially rescued by the addition of the observed feedback levels of insulin (10 ng ml -1 ) induced by BKM120 in mice. n = 3 biologically independent samples per arm, mean ± s.d. number of cells. b, Cell viability assay demonstrating the effects of feedback levels of insulin on two patient-derived organoid cultures (PtA and PtB) being treated in a dose response with BKM120 as measured by cell titre-glo at 96 h. n = 3 biologically independent samples per treatment. c, Proliferation in minimal growth medium of mouse TNBC cells treated with PI3K inhibitors partially rescued by the addition of the observed feedback levels of insulin induced by BKM120 in mice (Fig. 1) . n = 6 biologically independent samples per treatment, mean ± s.d. d, e, Proliferation of HCT116-neo cells (d) and HCT116 PTEN knockout (KO) cells (e) with and without treatment with physiologically observed levels of insulin (10 ng ml -1 ) and treatment with the clinically relevant PI3K inhibitors GDC-0032 and BYL-719. n = 4 biologically independent samples per treatment, mean ± s.d. confluence. f, g, Proliferation of DLD1-Neo cells (f) and DLD-1 PTEN knockout cells (g) under the same treatment conditions as in d and e. Of note, the loss of PTEN in these isogenic sets of colon cancer lines does not uniformly alter the response to insulin in the setting of PI3K inhibition. In the context of PTEN loss, physiological levels of insulin can restore normal proliferation in HCT116 cells despite the presence of PI3K inhibitors. n = 4 biologically independent samples per treatment, mean ± s.d. confluence.
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